Phastar Achieves B Rating in CDP, Strengthening Our Leadership in Corporate Responsibility 

2 minute read

Published: March 24th, 2025

As we celebrate B Corp Month, Phastar reaffirms its commitment to responsible business practices that drive real impact. We continue to drive sustainability through initiatives such as our net-zero targets, pro bono biometrics support for charities, and ESG-driven clinical trial solutions. 

Additionally, we are proud to announce that Phastar has improved its CDP sustainability score, achieving a commendable B rating this year. This progress reflects our commitment to environmental transparency and action, recognizing the measurable steps we have taken to enhance emissions management, climate risk assessment, and sustainability initiatives. 

CDP is a global non-profit that runs the world’s only independent environmental disclosure system for companies to manage their environmental impacts. Achieving a B rating places Phastar in the Management band, highlighting our dedication to integrating climate considerations into our operations and decision-making. 

This recognition reinforces our mission to lead the CRO industry in responsible business practices that benefit our communities, employees, clients, and the environment. 

This B Corp Month, we celebrate the businesses proving that corporate responsibility isn’t just an ideal—it’s a necessity. We’re proud to be leading the charge in the CRO space, showing that scientific excellence and ethical leadership go hand in hand. 

Related articles

Designing Real-World Evidence for Causal Interpretation 

Designing Real-World Evidence for Causal Interpretation 

March 24th, 2026 4 minute read

Causal inference begins with clarity about the research question. What population, treatment, comparator, and outcome...

Building a Purpose-Driven Organization: Leading in Corporate Responsibility  

Building a Purpose-Driven Organization: Leading in Corporate Responsibility  

March 23rd, 2026 3 minute read

As we mark B Corp Month 2026, Phastar is reaffirming its commitment to building a purpose-driven organization where p...

Inserting Dose Levels Mid-Trial: A Smarter Approach for Early-Phase Oncology Combination Studies 

Inserting Dose Levels Mid-Trial: A Smarter Approach for Early-Phase Oncology Combination Studies 

March 18th, 2026 5 minute read

Early-phase oncology trials are increasingly exploring combination therapies to improve outcomes for patients with co...